EA201991998A1 - ARIL-HYDROCARBONIC RECEPTOR ANTAGONISTS AND THEIR APPLICATION - Google Patents

ARIL-HYDROCARBONIC RECEPTOR ANTAGONISTS AND THEIR APPLICATION

Info

Publication number
EA201991998A1
EA201991998A1 EA201991998A EA201991998A EA201991998A1 EA 201991998 A1 EA201991998 A1 EA 201991998A1 EA 201991998 A EA201991998 A EA 201991998A EA 201991998 A EA201991998 A EA 201991998A EA 201991998 A1 EA201991998 A1 EA 201991998A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor antagonists
stem cells
hematopoietic stem
methods
relates
Prior art date
Application number
EA201991998A
Other languages
Russian (ru)
Inventor
Артур Гленн Ромеро
Кевин А. Гонкалвес
Original Assignee
Маджента Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маджента Терапьютикс, Инк. filed Critical Маджента Терапьютикс, Инк.
Priority claimed from PCT/US2018/027265 external-priority patent/WO2018191476A1/en
Publication of EA201991998A1 publication Critical patent/EA201991998A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к антагонистам арил-гидрокарбонового рецептора, таким как замещенные имидазопиридины и имидазопиразины, а также к способам размножения гемопоэтических стволовых клеток посредством культивирования гемопоэтических стволовых клеток или клеток-предшественников в присутствии этих агентов. Кроме того, настоящее изобретение относится к способам лечения различных патологий у пациента путем введения размноженных гемопоэтических стволовых клеток. Настоящее изобретение также относится к способам синтеза антагонистов арил-гидрокарбонового рецептора, таких как замещенные имидазопиридины и имидазопиразины, а также к наборам, содержащим антагонисты арил-гидрокарбонового рецептора, которые могут быть использованы для размножения гемопоэтических стволовых клеток.The present invention relates to aryl-hydrocarbon receptor antagonists such as substituted imidazopyridines and imidazopyrazines, as well as methods for propagating hematopoietic stem cells by culturing hematopoietic stem cells or progenitor cells in the presence of these agents. In addition, the present invention relates to methods of treating various pathologies in a patient by administering expanded hematopoietic stem cells. The present invention also relates to methods for synthesizing aryl-hydrocarbon receptor antagonists such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl-hydrocarbon receptor antagonists, which can be used to propagate hematopoietic stem cells.

EA201991998A 2018-02-02 2018-04-12 ARIL-HYDROCARBONIC RECEPTOR ANTAGONISTS AND THEIR APPLICATION EA201991998A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625896P 2018-02-02 2018-02-02
PCT/US2018/027265 WO2018191476A1 (en) 2017-04-12 2018-04-12 Aryl hydrocarbon receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
EA201991998A1 true EA201991998A1 (en) 2020-03-03

Family

ID=69942851

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991998A EA201991998A1 (en) 2018-02-02 2018-04-12 ARIL-HYDROCARBONIC RECEPTOR ANTAGONISTS AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201991998A1 (en)

Similar Documents

Publication Publication Date Title
ZA201906209B (en) Aryl hydrocarbon receptor antagonists and uses thereof
MY194764A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
EA201992670A1 (en) METHOD FOR OBTAINING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES
EA202091709A1 (en) DNA PC INHIBITORS
EA201990048A1 (en) [1,2,4] TRIAZOLO [1,5-a] PYRIDINYL-SUBSTITUTED INDOL COMPOUNDS
EA201892147A1 (en) BICYCLIC COMPOUNDS
CY1122456T1 (en) MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER
EA202192736A1 (en) ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND TO PSMA
EA201592074A1 (en) COMPOSITIONS AND METHODS OF CHANGING THE SIGNAL SYSTEM OF THE SECONDARY MESSENGER
BR112015017307A2 (en) compositions of low acid species and methods for their production and use
NO20084878L (en) Humanized C-kit antibody
EA201791270A1 (en) MODIFIED APRIL-BINDING ANTIBODIES
EA202091708A1 (en) DNA PC INHIBITORS
EA201790818A1 (en) 2-AMINO-6- (DIFTOROMETIL) -5,5-DIFTOR-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
EA202092202A1 (en) ROR ANTIBODY CONSTRUCTIONS
EA201792034A1 (en) SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS
EA202290054A1 (en) POLYSPECIFIC ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND TO CD22 AND CD3
MX2021010916A (en) Rad51 inhibitors.
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
EA201390467A1 (en) ANTIBODY COMPOSITIONS AND METHODS OF APPLICATION
EA202190807A1 (en) ANTIBODIES TO SYNUCLEINE
EA202190094A1 (en) ANTIBODIES AGAINST CD40 FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
EA202190810A1 (en) METHODS AND KITS FOR OBTAINING WHOLE BLOOD WITH INACTIVATED PATHOGEN
EA202092125A1 (en) ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION